donwloadimg

Download App

Log in to access Online Inquiry
Multi-dimentional Analyses
Company Valuation Capital Tracking Short Selling Data
SUPN Supernus Pharmaceuticals
28.380
-0.610-2.10%
Post Mkt Price
28.38000.00%
YOY
Do not show
Hide blank lines
(Q1)2022/03/31(FY)2021/12/31(Q4)2021/12/31(Q3)2021/09/30
Total revenue
16.48% 152.51M 11.41% 579.78M 10.79% 159.05M -4.3% 148.46M
Operating revenue
16.48% 152.51M 11.41% 579.78M 10.79% 159.05M -4.3% 148.46M
Cost of revenue
19.91% 17.93M 43.09% 75.06M -8.3% 16.99M -15.44% 18.09M
Gross profit
16.03% 134.57M 7.86% 504.71M 13.62% 142.06M -2.52% 130.38M
Operating expense
29.68% 131.94M 45.45% 425.22M 67.86% 134.84M 25.88% 97.7M
Selling and administrative expenses
47.19% 90.46M 51.87% 304.76M 80.06% 101.74M 31.78% 72.03M
-Selling and marketing expense
57.39% 60.51M 48.2% 199.71M -- -- 29.44% 50.7M
-General and administrative expense
30.14% 29.95M 59.35% 105.05M -- -- 37.7% 21.33M
Research and development costs
-39.21% 20.84M 19.1% 90.47M 17.5% 21.08M 16.72% 19.65M
Depreciation amortization depletion
243.67% 20.64M 90.99% 29.99M 104.23% 12.03M -1.62% 6.01M
-Depreciation and amortization
243.67% 20.64M 90.99% 29.99M 104.23% 12.03M -1.62% 6.01M
Operating profit
-81.51% 2.63M -54.73% 79.5M -83.85% 7.22M -41.78% 32.68M
Net non-operating interest income expense
658.25% 12.76M -154.53% -12.85M -22.45% -4.05M -28.95% -3.64M
Non-operating interest income
285.57% 14.7M -43.49% 10.57M -32.39% 1.89M -30.07% 2.28M
Non-operating interest expense
-68.15% 1.94M -1.39% 23.42M -2.66% 5.93M -2.68% 5.93M
Other net income (expense)
34.8% -665K 443.68% 6.53M 34.12% -1.12M 86.73% -80K
Special income (charges)
34.8% -665K 443.68% 6.53M 34.12% -1.12M -- -80K
-Less:Restructuring and merger&acquisition
-34.8% 665K -443.68% -6.53M -34.12% 1.12M -- 80K
Income before tax
34.71% 14.72M -56.61% 73.18M -94.83% 2.05M -45.06% 28.96M
Income tax
-308.08% -10.89M -52.63% 19.75M -104.38% -391K -41.81% 7.4M
Net income
349.88% 25.62M -57.92% 53.42M -92.06% 2.44M -46.09% 21.56M
Net income continuous Operations
349.88% 25.62M -57.92% 53.42M -92.06% 2.44M -46.09% 21.56M
Minority interest income
Net income attributable to the parent company
349.88% 25.62M -57.92% 53.42M -92.06% 2.44M -46.09% 21.56M
Preferred stock dividends
Other preferred stock dividends
Net income attributable to common stockholders
349.88% 25.62M -57.92% 53.42M -92.06% 2.44M -46.09% 21.56M
Basic earnings per share
336.36% 0.48 -58.09% 1.01 -91.38% 0.05 -46.05% 0.41
Diluted earnings per share
290.91% 0.43 -58.47% 0.98 -92.98% 0.04 -45.95% 0.4
Dividend per share
Currency Unit
USDUSDUSDUSD
Accounting Standards
US-GAAPUS-GAAPUS-GAAPUS-GAAP
Audit Opinions
--Unqualified Opinion----

FY: Financial Year Annual Report, which is equivalent to the 10-K file disclosed by the listed company to the SEC.

Q: Quarterly report, which is equivalent to the 10-Q file disclosed by the listed company to the SEC, where Q1, Q2, Q3, and Q4 are single quarterly reports with a span of 3 months; Q6 and Q9 are cumulative quarterly reports, and Q6 is 6 months , Q9 is 9 months.

The MOM data from the Quarterly report,MOM=(current period - last period)/last period *100%

Company Overview More
Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. Its commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset epilepsy seizures in adults and children between 6 to 17 years of age. The company’s commercial products also comprise Qelbree, a selective norepinephrine reuptake inhibitor indicated for the treatment of attention-deficit hyperactivity disorder (ADHD) in pediatric patients 6 to 17 years of age; APOKYN for the acute intermittent treatment of hypomobility or off episodes in patients with advanced Parkinson’s Disease (PD); XADAGO for treating levodopa/carbidopa in patients with PD experiencing off episodes; MYOBLOC, a Type B toxin product indicated for the treatment of cervical dystonia and sialorrhea in adults; GOCOVRI for the treatment of dyskinesia in patients with PD; and Osmolex ER for the treatment of Parkinson's disease and drug-induced extrapyramidal reaction in adult patients. In addition, its product candidates include Qelbree (SPN-812), which has completed Phase III clinical trials that is used for the treatment of ADHD; SPN-830, a late-stage drug/device combination product candidate for the prevention of off episodes in PD patients; SPN-817, a novel product candidate in Phase I clinical trials for the treatment of severe epilepsy; SPN-820, a product candidate in Phase II clinical trials for treating resistant depression; and SPN-443 and SPN-446, which are in preclinical stage for treating CNS. The company markets and sells its products through pharmaceutical wholesalers, specialty pharmacies, and distributors. The company was incorporated in 2005 and is headquartered in Rockville, Maryland.
CEO: Khattar, Jack A.
Market: NASDAQ
Hot List
TradeSearchNews
SymbolLatest price%Chg

Loading...